본문 바로가기
HOME> 저널/프로시딩 > 저널/프로시딩 검색상세

저널/프로시딩 상세정보

권호별목차 / 소장처보기

H : 소장처정보

T : 목차정보

Hematology/oncology and stem cell therapy 10건

  1. [해외논문]   Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies  

    Rafei, Hind (Department of Internal Medicine, George Washington University School of Medicine, Washington, DC, USA ) , Kharfan-Dabaja, Mohamed A. (Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA)
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 1 - 12 , 2018 , 1658-3876 ,

    초록

    Abstract More effective therapies are emerging, with better toxicity profiles, and are being incorporated into modern treatment algorithms of chronic lymphocytic leukemia at various stages of the disease, including for patients harboring Del17p and/or aberrant TP53 . Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, has demonstrated impressive response rates in the relapsed/refractory setting, including in the setting of Del17p and/or TP53 mutations. Venetoclax, an inhibitor of BCL-2 known to play an important role in regulating cell death, has been approved recently for treatment of patients with chronic lymphocytic leukemia with Del17p who have received at least one prior therapy. Unfortunately, a cure remains unattainable unless eligible patients are offered an allogeneic hematopoietic cell transplant. However, hematopoietic cell allografting is limited by the availability of suitable donors and significant morbidity and mortality. Recent clinical practice recommendations by the American Society for Blood and Marrow Transplantation have relegated the role of transplantation to later stages of the disease. In patients with evidence of Richter syndrome, frontline consolidation allogeneic hematopoietic cell transplantation remains the most desirable approach owing to the limited activity of ibrutinib or other novel therapies. Further therapeutic advances would require enrolling these patients in large clinical trials that evaluate novel therapies alone or in combination with traditional chemotherapies or even in the setting of posttransplant consolidation/maintenance.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  2. [해외논문]   Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience  

    Atilla, Pinar Ataca (Corresponding author at: Department of Hematology & BMT Unit, School of Medicine, Ankara University, Cebeci Hospital, Dikimevi, Ankara 06590, Turkey.) , Atilla, Erden , Bozdag, Sinem Civriz , Yuksel, Meltem Kurt , Toprak, Selami Kocak , Topcuoglu, Pervin , Demirer, Taner , Ilhan, Osman , Arslan, Onder , Gurman, Gunhan , Ozcan, Muhit
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 13 - 17 , 2018 , 1658-3876 ,

    초록

    Abstract Objective/Background Primary central nervous system lymphoma (PCNSL) is associated with worst prognosis compared with other aggressive non-Hodgkin’s lymphomas. However, recent trials have demonstrated that long-term progression-free survival can be achieved by immunochemotherapy. Our goal is to present our experience in aggressive PCNSL in this study. Methods We retrospectively evaluated the clinical features and management of 13 PCNSL patients who were diagnosed and treated between 2006 and 2015. Results Nine patients received rituximab (R) 375mg/m 2 /day on Day 1, methotrexate (MTX) 3.5g/m 2 /day and cytosine arabinoside (ARA-C) 4.4g/m 2 /day on Day 2, as well as ARA-C 4.4g/m 2 /day on Day 3 every 28days, and underwent autologous stem cell transplantation. Two patients received procarbazine instead of ARA-C. One patient relapsed, and allogeneic hematopoietic stem cell transplantation was performed. All nine patients are followed in complete remission. Two of 13 patients received one course of MTX and 36–45Gy radiotherapy and died. One patient with renal transplantation had progressive disease and died. Grade 3–4 hematological toxicity was detected in 11 (85%), Grade 3–4 mucositis in 11 (85%), and febrile neutropenia in 12 (92%) patients. The median overall survival in the R–MTX–ARA-C/procarbazine group was 28±16months. Conclusion R–MTX–ARA-C followed by autologous stem cell transplantation seems a promising strategy with high response rates in PCNSL.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  3. [해외논문]   Hematological parameters and red blood cell morphological abnormality of Glucose-6-Phosphate dehydrogenase deficiency co-inherited with thalassemia  

    Pengon, Jutharat (Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand ) , Svasti, Saovaros (Thalassemia Research Centre, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand ) , Kamchonwongpaisan, Sumalee (Medical Molecular Biology Research Unit, BIOTEC, National Science and Technology Development Agency, Pathum Thani, Thailand ) , Vattanaviboon, Phantip (Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand)
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 18 - 24 , 2018 , 1658-3876 ,

    초록

    Abstract Objective/Background Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and thalassemia are genetically independent hemolytic disorders. Co-inheritance of both disorders may affect red blood cell pathology to a greater extent than normally seen in either disorder alone. This study determines the prevalence and evaluates hematological changes of G-6-PD deficiency and thalassemia co-inheritance. Methods G-6-PD deficiency was screened from 200 male thalassemia blood samples using a fluorescent spot test. Hematological parameters and red blood cell morphology were evaluated among G-6-PD deficiency/thalassemia co-inheritance, G-6-PD deficiency alone, thalassemia alone, and normal individuals. Results G-6-PD deficiency was detected together with hemoglobin (Hb) E heterozygote, Hb E homozygote, β-thalassemia trait, and β-thalassemia/Hb E, α-thalassemia-2 trait, and Hb H disease. Hb level, hematocrit, mean cell volume, and mean cell Hb of G-6-PD deficiency co-inherited with asymptomatic thalassemia carriers show significantly lower mean values compared to carriers with only the same thalassemia genotypes. Higher mean red blood cell distribution width was observed in G-6-PD deficiency co-inherited with Hb E heterozygote, as with numbers of hemighost cells in G-6-PD deficiency/thalassemia co-inheritance compared to those with either disorder. Apart from Hb level, hematological parameters of co-inheritance disorders were not different from individuals with a single thalassemia disease. Conclusion G-6-PD deficiency co-inherited with thalassemia in males was present in 10% of the participants, resulting in worsening of red blood cell pathology compared with inheritance of thalassemia alone.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  4. [해외논문]   Impact of vitamin D deficiency on increased blood eosinophil counts  

    Souto Filho, Joã (Faculdade de Medicina de Campos, Campos dos Goytacazes, Rio de Janeiro, Brazil ) , o Tadeu Damian (Faculdade de Medicina de Campos, Campos dos Goytacazes, Rio de Janeiro, Brazil ) , de Andrade, Alí (Faculdade de Medicina de Campos, Campos dos Goytacazes, Rio de Janeiro, Brazil ) , cia Souza (Faculdade de Medicina de Campos, Campos dos Goytacazes, Rio de Janeiro, Brazil ) , Ribeiro, Felipe Mesquita (Faculdade de Medicina de Campos, Campos dos Goytacazes, Rio de Janeiro, Brazil) , Alves, Paola de Araujo Sardenberg , Simonini, Virgí , nia Ribeiro Fernandes
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 25 - 29 , 2018 , 1658-3876 ,

    초록

    Abstract Objective/background Vitamin D has been increasingly recognized as an immunomodulatory agent. Its deficiency has been associated with immune-mediated diseases such as asthma, rhinitis, and atopic dermatitis. These allergic conditions are dependent on T-helper type 2 (Th2) cells secreting interleukins, overproduction of immunoglobulin E (IgE), and eosinophil activation. We investigated the association between serum vitamin D levels and blood absolute eosinophil count. Methods We carried out a cross-sectional study of 669 men and women referred to a clinical pathology laboratory who underwent 25-hydroxyvitamin D testing and complete blood count analysis on the same day. Results Vitamin D levels were stratified into four ranges: severely deficient ( p = .001). The difference was significant between the severe deficiency group and each of the other three groups ( p = .012, p = .002, and p = .001, respectively). There was no statistical difference among the four groups in terms of total leukocyte counts ( p = .151), neutrophils ( p = .177), or lymphocytes ( p = .582). Conclusion Vitamin D deficiency was associated with higher blood eosinophil count. These results support the possible role of vitamin D in the eosinophil immune response.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  5. [해외논문]   Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer  

    Castrellon, Aurelio B. , Velez, Michel , Nguyen, Steven M. , Blaya, Marcelo , Barnick, Sandra , Dumais, Katerine , LeCroy, Nicholas , Raez, Luis E.
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 30 - 33 , 2018 , 1658-3876 ,

    초록

    Abstract Objective To evaluate the effectiveness and tolerability of neoadjuvant chemotherapy with weekly paclitaxel in combination with weekly carboplatin area under curve 2 followed by anthracycline chemotherapy. Patients and methods This is a retrospective review of electronic medical records of patients ( N = 32) with stage 1c–III triple-negative breast cancer. Patients received neoadjuvant chemotherapy with paclitaxel 80 mg/m 2 once per week for 12 weeks in combination with carboplatin area under curve 2 once per week for 12 weeks (wP + wCb), followed by a standard anthracycline regimen including either doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 every 2 or 3 weeks, or epirubicin 90 mg/m 2 and cyclophosphamide 600 mg/m 2 every 3 weeks for four cycles with myeloid growth factor support. Results Most patients (91%) received all 12 cycles of wP + wCb, and 88% received all four planned cycles of anthracycline chemotherapy. Of the patients, 84% completed all planned therapies. The complete pathologic response rate was 60%. In terms of hematologic toxicity, 96% of the patients experienced grade ≥3 leucopenia, 40% grade ≥3 anemia, and 15% grade ≥3 thrombocytopenia, and neutropenic fever was seen in 22% of the patients. Conclusion The combination of neoadjuvant chemotherapy with wP + wCb before anthracycline chemotherapy can be tolerated by patients with triple-negative breast cancer. Complete pathologic response rates were comparable with those historically seen. Careful selection of patients is fundamental as this regimen is associated with a high incidence of hematologic toxicity.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  6. [해외논문]   Severe Plasmodium vivax cerebral malaria complicated by hemophagocytic lymphohistiocytosis treated with artesunate and doxycycline  

    Amireh, Sawsan (Corresponding author at: Department of Hematology and Oncology, Saint Michael's Medical Center, New York Medical College, 111 Central Avenue, Newark, NJ 07102, USA.) , Shaaban, Hamid , Guron, Gunwant
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 34 - 37 , 2018 , 1658-3876 ,

    초록

    Abstract Malaria-related hemophagocytic lymphohistiocytosis is a rare, potentially fatal, hyperinflammatory disease entity which can be challenging to diagnose and treat. It is usually associated with Plasmodium falciparum infection. It is less frequently associated with Plasmodium vivax . Here we report an unusual case of a 23-year-old healthy Nigerian man who presented with fever, microangiopathic hemolytic anemia, acute renal failure, and confusion, and was diagnosed as having cerebral malaria-related hemophagocytic lymphohistiocytosis caused by P. vivax infection. He was successfully treated with intravenous artesunate and doxycycline with dramatic clinical improvement.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  7. [해외논문]   Polycythemia vera masked due to severe iron deficiency anemia  

    Kambali, Shweta (Corresponding author at: Department of Hematology and Oncology, St Mary's of Michigan, Central Michigan University College of Medicine Health Partners, 800 South Washington Avenue, Saginaw, MI 48601, USA.) , Taj, Asma
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 38 - 40 , 2018 , 1658-3876 ,

    초록

    Abstract Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass and an increased leukocyte count with decreased erythropoietin. We present a case where there was a delay in the diagnosis of polycythemia because of menorrhagia in the past. On admission, the patient presented with elevated red and white blood cell counts, erythropoietin was low, and polycythemia was then suspected. A bcr-abl test was performed to rule out chronic myelogenous leukemia. JAK2 mutation was positive, and the patient was diagnosed with polycythemia vera.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  8. [해외논문]   End of therapy minimal residual disease (MRD) measurement in children with ALL does not predict relapse  

    Sarrawi, Tahani Hani (Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan ) , Zayyat, Ismael (Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan ) , Barakat, Fareed (Department of Pathology, King Hussein Cancer Center, Amman, Jordan ) , Rezeq, Maha (Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan ) , Jmaian, Salam Abu (Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan ) , Madanat, Faris (Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan)
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 41 - 43 , 2018 , 1658-3876 ,

    초록

    Abstract Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass and an increased leukocyte count with decreased erythropoietin. We present a case where there was a delay in the diagnosis of polycythemia because of menorrhagia in the past. On admission, the patient presented with elevated red and white blood cell counts, erythropoietin was low, and polycythemia was then suspected. A bcr-abl test was performed to rule out chronic myelogenous leukemia. JAK2 mutation was positive, and the patient was diagnosed with polycythemia vera.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  9. [해외논문]   Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation  

    Varela Gó (Departamento de Hematología, Hospital Universitario A Coruña, A Coruña, Spain ) , mez, Rosario (Departamento de Hematología, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain ) , Vá (Departamento de Hematología, Hospital Universitario A Coruña, A Coruña, Spain ) , zquez Vá (Departamento de Hematología, Hospital Universitario A Coruña, A Coruña, Spain ) , zquez, Goretti (Departamento de Hematología, Hospital Universitario A Coruña, A Coruña, Spain) , Noriega Concepció , n, Victor , Galego Garcí , a, Andrea , Andó , n Saavedra, Concepció , n
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 44 - 46 , 2018 , 1658-3876 ,

    초록

    Abstract The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  10. [해외논문]   Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation  

    Bagal, Bhausaheb (Department of Medical Oncology, Tata Memorial Center, Mumbai, India ) , Chandrasekharan, Arun (Department of Medical Oncology, Tata Memorial Center, Mumbai, India ) , Chougle, Aliya (Department of Nursing, Tata Memorial Center, Mumbai, India ) , Khattry, Navin (Department of Medical Oncology, Tata Memorial Center, Mumbai, India)
    Hematology/oncology and stem cell therapy v.11 no.1 ,pp. 47 - 51 , 2018 , 1658-3876 ,

    초록

    Abstract Objective/background Hepatic veno-occlusive disease (VOD) is well recognized potentially serious regimen-related toxicity seen after stem cell transplantation. Severe VOD is associated with poor long-term outcomes with very high mortality. Besides supportive care, only defibrotide has been found to be effective in the management of VOD. The recommended dose of defibrotide is 25mg/kg/d but there has been no classical dose finding study done for this drug. A higher dose of defibrotide is associated with increased risk of bleeding and this drug is prohibitively expensive. We report our experience of using fixed low dose of defibrotide in patients with VOD. Methods We retrospectively evaluated 511 patients who underwent stem cell transplant at our center from November 2007 and December 2015. All patients received ursodeoxycholic acid as VOD prophylaxis. Modified Seattle criterion was used for diagnosis and severity grading of VOD. Patients developing VOD were initially treated with furosemide and adequate analgesia. Defibrotide was started within 12 to 24 hours of diagnosis of VOD. All adult patients received defibrotide at a fixed dose of 200mg twice daily while two children were given dose of 100mg and 50mg twice daily. Results Nine (1.7%) of our patients developed VOD. Daily dose of defibrotide ranged from 5mg/kg/d to 20mg/kg/d till resolution of VOD. All patients had complete resolution of VOD. None of our patients required ventilator support or dialysis. No episodes of bleeding were observed. No dose response relationship was observed between defibrotide dose and time to resolution of VOD. Conclusion Low fixed dose defibrotide initiated early seems to be effective and safe in treatment of VOD. This is relevant in a resource limited setting and warrants prospective evaluation.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지

논문관련 이미지